Skip to main content

AI Bias Analysis

4 models · Takes ~15 seconds

Related Economy Stories

Portal CEO on Lilly Deal for Cancer Biotech CrossBridge
Bloomberg Markets

Portal CEO on Lilly Deal for Cancer Biotech CrossBridge

Portal Innovations CEO John Flavin provides a look into the 2026 biotech M&A pipeline and breaks down Eli Lilly’s purported acquisition of CrossBridge Bio for up to $300 million, bolstering its oncology segment. He talks with Katie Greifeld and Romaine Bostick on “The Close.” (Source: Bloomberg)

Read more →
Advertisement